MARGARET RINCKHOFF: Open Payments
NPI 1093108821 · PARAMUS, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,924 in 105 payments from 15 companies in 2025. Trend: 2023 $1,121 · 2024 $1,372 · 2025 $1,924
Food & beverage: $1,924
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 17 | $332 |
| Alkermes, Inc. | 13 | $284 |
| Vanda Pharmaceuticals Inc. | 12 | $228 |
| Janssen Pharmaceuticals, Inc | 12 | $211 |
| Teva Pharmaceuticals USA, Inc. | 11 | $177 |
| Otsuka America Pharmaceutical, Inc. | 9 | $165 |
| E.R. Squibb & Sons, L.L.C. | 9 | $144 |
| Luye Pharma (USA) Ltd. | 6 | $111 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $79 |
| Lundbeck LLC | 4 | $74 |
Products named: INGREZZA, ARISTADA, INVEGA SUSTENNA, FANAPT, REXULTI, COBENFY, ERZOFRI EXTENDED-RELEASE, UZEDY.
Industry payments across NJ — which companies pay providers there.
